NeOnc to host Nov 12 call to update on NEO100-1 trial and compassionate use data

NEONC TECHNOLOGIES HOLDINGS, INC.

Investor call on Nov 12, 2025 at 9:00 a.m. ET to present data updates from Phase 1/2a NEO100-1 trial.
Discussion to include MRI radiographic response, progression-free survival (PFS), and overall survival (OS) trends.
Participants include Duke and NYU Langone neuro-oncologists; management team present.
No specific clinical results disclosed in the press release; call may provide new data.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.